Increasingly, genomic profiling is being used to advance cancer treatment, utilising detailed genetic mapping to enable earlier diagnoses and personalised therapies. The essence of this lies in genome sequencing, notably through techniques such as Next Generation Sequencing (NGS), which provide key insights about the nature of the disease. However, the analytical complexity of genome sequencing introduces significant uncertainties. Metrology (measurement science) is fundamental to overcome these challenges and provide confidence in data to support timely access to accurate cancer diagnostics and therapies. A new EU project under the European Partnership for Metrology, seeks to address these challenges.

GenomeMET, a collaborative project, is focused on developing a robust metrological (measurement) infrastructure to support method validation and quality control at both the pre-analytical and analytical stages. The consortium, led by the Istituto Nazionale di Ricerca Metrologica (INRiM – the Italian metrology institute) includes leading European metrology institutes, instrument manufacturers, EQA scheme providers, regulatory bodies, and clinical laboratories. The project will also develop reference measurement procedures for measuring genomic biomarkers. This will support improved accuracy and comparability of genomic profiling across European healthcare systems in support of Horizon Europe’s Mission on Cancer.

NIB acts as a consortium partner within the GenomeMET project and leads one of the working packages. Researchers from NIB are involved in the project under the guidance of Assist. Dr. Mojca Milavec and Dr. Alexadra Bogožalec Košir from the Department of Biotechnology and Systems Biology and Assist. dr. Metka Novak and Assist. Dr. Barbara Breznik from the Department of Genetic Toxicology and Cancer Biology.

Project partners:


GenomeMET in short:


Follow project on webpage and social media:

• GenomeMET: Overview | LinkedIn
• HOME | Genomemet-ComingSoon